ARCHIVES

Over Half of ALK-Positive NSCLC Patients Responded To Crizotinib In Colorado Study

This article is from The Cancer Letter archive.

Vol. 33 No. 11 | November 26, 2010

Download PDF Visit The Full Archive

Related Articles

Larry Norton Is President-Elect Of ASCO; Rauscher Is Cancer Research Editor-In-Chief.

March 3, 2000

CIS Cost Sharing Feasibility Study Recommended

December 11, 1987

Animal Diagnostic Lab concept OK’d

February 18, 1994

NCI Awards $10 Million To States for Cervix Screening

September 27, 1974

Long-Term Effect Of One Phase III Trial: Benefit For Thousands Of Patients

November 27, 2009

Patient Advocacy: Breast Cancer Coalition Forms PAC To Increase Political Activities

April 18, 1997